Targeted Oncology

Tafasitamab Plus R-CHOP Improves PFS in First-Line DLBCL: Phase 3 Results

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.
News Medical on MSN

Dresden study uncovers new key mechanism in cancer cells

A study by the Mildred Scheel Early Career Center group led by Dr. Mohamed Elgendy at the TUD Faculty of Medicine provides ...